HomeCompareFGEN vs CL

FGEN vs CL: Dividend Comparison 2026

FGEN yields 22.05% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGEN wins by $41.9K in total portfolio value
10 years
FGEN
FGEN
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full FGEN calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — FGEN vs CL

📍 FGEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGENCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGEN + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGEN pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGEN
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, FGEN beats the other by $2,497.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGEN + CL for your $10,000?

FGEN: 50%CL: 50%
100% CL50/50100% FGEN
Portfolio after 10yr
$61.8K
Annual income
$6,871.04/yr
Blended yield
11.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

FGEN
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$28.00
+208.7% upside vs current
Range: $28.00 — $28.00
Altman Z
-20.3
Piotroski
6/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGEN buys
0
CL buys
0
No recent congressional trades found for FGEN or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGENCL
Forward yield22.05%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$82.7K$40.8K
Annual income after 10y$8,340.12$5,401.96
Total dividends collected$49.4K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$28.00$92.45

Year-by-year: FGEN vs CL ($10,000, DRIP)

YearFGEN PortfolioFGEN Income/yrCL PortfolioCL Income/yrGap
1← crossover$12,905$2,205.07$11,012$312.01+$1.9KFGEN
2$16,468$2,659.50$12,196$412.95+$4.3KFGEN
3$20,792$3,171.71$13,599$549.66+$7.2KFGEN
4$25,990$3,742.62$15,288$736.64+$10.7KFGEN
5$32,182$4,372.22$17,353$995.28+$14.8KFGEN
6$39,494$5,059.61$19,926$1,357.80+$19.6KFGEN
7$48,062$5,803.04$23,194$1,873.82+$24.9KFGEN
8$58,026$6,599.92$27,439$2,621.52+$30.6KFGEN
9$69,535$7,446.93$33,088$3,727.38+$36.4KFGEN
10$82,743$8,340.12$40,806$5,401.96+$41.9KFGEN

FGEN vs CL: Complete Analysis 2026

FGENStock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Full FGEN Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this FGEN vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGEN vs SCHDFGEN vs JEPIFGEN vs OFGEN vs KOFGEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.